sumatriptan ๐Ÿถ Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
serotonin (5-HT1) receptor agonists, sumatriptan derivatives 2543 103628-46-2

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • GR43175
  • GR 43175
  • sumatriptan
  • sumatriptan succinate
A serotonin agonist that acts selectively at 5HT1 receptors. It is used in the treatment of MIGRAINE DISORDERS.
  • Molecular weight: 295.40
  • Formula: C14H21N3O2S
  • CLOGP: 0.74
  • LIPINSKI: 0
  • HAC: 5
  • HDO: 2
  • TPSA: 65.20
  • ALOGS: -3.37
  • ROTB: 5

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
20 mg N
50 mg O
6 mg P
25 mg R

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 1 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 21.40 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 22 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 0.68 ยตM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 14 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 1.70 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 19 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.83 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 1.70 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
Dec. 28, 1992 FDA GLAXOSMITHKLINE

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Product physical issue 4111.33 11.52 911 42648 3421 50558144
Product dose omission issue 1040.04 11.52 1016 42543 182822 50378743
Application site erythema 560.14 11.52 192 43367 4346 50557219
Migraine 494.45 11.52 453 43106 74827 50486738
Product quality issue 491.55 11.52 315 43244 30543 50531022
Application site burn 376.73 11.52 95 43464 681 50560884
Device deployment issue 332.86 11.52 122 43437 3374 50558191
Device malfunction 330.06 11.52 189 43370 14932 50546633
Application site pain 326.63 11.52 123 43436 3675 50557890
Application site discolouration 263.42 11.52 71 43488 679 50560886
Device issue 257.89 11.52 179 43380 19793 50541772
Application site paraesthesia 191.73 11.52 36 43523 39 50561526
Accidental exposure to product 143.83 11.52 135 43424 22922 50538643
Application site urticaria 136.77 11.52 34 43525 228 50561337
Application site rash 131.87 11.52 56 43503 2301 50559264
Application site irritation 123.42 11.52 48 43511 1567 50559998
Medication overuse headache 119.52 11.52 37 43522 598 50560967
Colitis ischaemic 117.73 11.52 83 43476 9400 50552165
Application site warmth 113.88 11.52 27 43532 144 50561421
Application site pruritus 109.79 11.52 57 43502 3702 50557863
Headache 99.53 11.52 760 42799 505775 50055790
Death 96.58 11.52 83 43476 325296 50236269
Needle issue 95.74 11.52 66 43493 7209 50554356
Arteriospasm coronary 94.83 11.52 50 43509 3352 50558213
Anxiety 89.10 11.52 345 43214 177261 50384304
Application site scar 81.84 11.52 22 43537 208 50561357
Injection site pain 78.66 11.52 242 43317 110782 50450783
Application site vesicles 78.49 11.52 33 43526 1322 50560243
Paraesthesia 76.89 11.52 253 43306 119990 50441575
Injection site haemorrhage 74.64 11.52 92 43467 21254 50540311
Application site swelling 73.04 11.52 24 43535 474 50561091
Glossodynia 71.41 11.52 8 43551 115561 50446004
Reversible cerebral vasoconstriction syndrome 70.24 11.52 35 43524 2084 50559481
Throat tightness 69.93 11.52 88 43471 20759 50540806
IIIrd nerve paresis 66.79 11.52 17 43542 127 50561438
Product substitution issue 66.77 11.52 71 43488 13986 50547579
Acute kidney injury 65.40 11.52 60 43499 227998 50333567
Device power source issue 65.12 11.52 22 43537 475 50561090
Wrong technique in product usage process 64.97 11.52 146 43413 55364 50506201
Systemic lupus erythematosus 63.37 11.52 21 43538 140601 50420964
Muscle twitching 63.02 11.52 72 43487 15359 50546206
Anaemia 61.69 11.52 76 43483 252380 50309185
Cerebral vasoconstriction 60.28 11.52 25 43534 967 50560598
Product leakage 59.80 11.52 21 43538 511 50561054
Application site exfoliation 58.72 11.52 18 43541 281 50561284
Infusion related reaction 56.95 11.52 38 43521 169519 50392046
Coronary artery dissection 56.95 11.52 22 43537 705 50560860
Arthropathy 54.93 11.52 34 43525 157872 50403693
Wound 54.82 11.52 12 43547 105782 50455783
Contraindicated product administered 54.75 11.52 30 43529 148928 50412637
Application site dryness 54.60 11.52 15 43544 155 50561410
Depression 53.32 11.52 282 43277 165141 50396424
Serotonin syndrome 52.69 11.52 84 43475 24629 50536936
Drug ineffective 51.96 11.52 990 42569 818343 49743222
Cholecystitis chronic 51.62 11.52 52 43507 9617 50551948
Application site reaction 51.39 11.52 20 43539 654 50560911
Product complaint 51.10 11.52 56 43503 11410 50550155
Treatment failure 50.18 11.52 28 43531 137609 50423956
Emotional distress 48.63 11.52 88 43471 28575 50532990
Dizziness 48.56 11.52 483 43076 345886 50215679
Abdominal discomfort 48.35 11.52 78 43481 231563 50330002
Application site scab 48.32 11.52 14 43545 178 50561387
Concussion 48.20 11.52 45 43514 7583 50553982
Device leakage 47.78 11.52 40 43519 5838 50555727
Post-traumatic neck syndrome 47.44 11.52 26 43533 1884 50559681
Somnambulism 47.42 11.52 37 43522 4887 50556678
Rheumatoid arthritis 47.36 11.52 63 43496 202487 50359078
Febrile neutropenia 46.86 11.52 13 43546 97654 50463911
Incorrect dose administered by device 46.84 11.52 32 43527 3443 50558122
Renal infarct 46.67 11.52 23 43536 1337 50560228
Pituitary tumour benign 46.33 11.52 25 43534 1756 50559809
Chest discomfort 45.51 11.52 179 43380 92543 50469022
Lower respiratory tract infection 45.07 11.52 13 43546 95188 50466377
Injection site bruising 44.47 11.52 98 43461 36670 50524895
Hostility 43.55 11.52 24 43535 1758 50559807
Cardiac failure 42.84 11.52 7 43552 76033 50485532
Libido increased 42.59 11.52 21 43538 1222 50560343
Neutropenia 42.30 11.52 39 43520 147926 50413639
Endometriosis 42.26 11.52 32 43527 4043 50557522
Soft tissue injury 41.90 11.52 22 43537 1462 50560103
Renal impairment 40.39 11.52 8 43551 75653 50485912
Application site inflammation 38.89 11.52 14 43545 367 50561198
Tension headache 38.85 11.52 26 43533 2705 50558860
Joint swelling 38.84 11.52 97 43462 245189 50316376
Disease progression 38.71 11.52 17 43542 95849 50465716
Expired product administered 38.41 11.52 34 43525 5348 50556217
Application site bruise 38.08 11.52 13 43546 290 50561275
Off label use 37.99 11.52 246 43313 474180 50087385
Nightmare 37.53 11.52 57 43502 16029 50545536
Atrial fibrillation 36.64 11.52 21 43538 101724 50459841
Pneumonia 36.30 11.52 185 43374 378216 50183349
Sternal fracture 35.76 11.52 22 43537 1980 50559585
Clonus 35.16 11.52 29 43530 4146 50557419
Hypotension 34.33 11.52 97 43462 235372 50326193
Suicidal ideation 33.99 11.52 115 43444 55270 50506295
Swelling 33.72 11.52 77 43482 200795 50360770
Alopecia 33.52 11.52 104 43455 244943 50316622
Nausea 33.49 11.52 818 42741 704580 49856985
Diarrhoea 33.37 11.52 335 43224 588141 49973424
Feeling abnormal 33.20 11.52 203 43356 125289 50436276
Angle closure glaucoma 32.93 11.52 21 43538 2013 50559552
Incorrect route of product administration 32.54 11.52 58 43501 18608 50542957
Drug specific antibody 32.46 11.52 20 43539 1805 50559760
Secondary adrenocortical insufficiency 32.43 11.52 17 43542 1126 50560439
Haemoglobin decreased 32.42 11.52 37 43522 127179 50434386
Muscle tightness 32.27 11.52 42 43517 10238 50551327
Hypoaesthesia 31.26 11.52 202 43357 127055 50434510
Therapeutic response unexpected 31.08 11.52 52 43507 15863 50545702
Infection 30.93 11.52 64 43495 172890 50388675
Pancytopenia 30.75 11.52 17 43542 84013 50477552
Transient global amnesia 30.59 11.52 12 43547 401 50561164
Dysgeusia 30.53 11.52 88 43471 38828 50522737
Pre-existing condition improved 30.48 11.52 34 43525 7063 50554502
Device defective 30.44 11.52 17 43542 1278 50560287
Chest pain 29.40 11.52 256 43303 176626 50384939
Hyponatraemia 29.09 11.52 24 43535 96115 50465450
Pharyngeal swelling 28.97 11.52 27 43532 4539 50557026
Peripheral swelling 28.44 11.52 87 43472 205849 50355716
Platelet count decreased 28.24 11.52 27 43532 100699 50460866
Hot flush 28.24 11.52 93 43466 44076 50517489
Application site discomfort 28.20 11.52 11 43548 362 50561203
Hyperkalaemia 28.06 11.52 4 43555 48085 50513480
Oxygen saturation decreased 28.01 11.52 14 43545 73234 50488331
Hepatic enzyme increased 27.95 11.52 47 43512 137333 50424232
Renal tubular acidosis 27.76 11.52 17 43542 1517 50560048
Interstitial lung disease 27.60 11.52 6 43553 53170 50508395
Sepsis 27.48 11.52 45 43514 132880 50428685
Application site erosion 27.38 11.52 9 43550 178 50561387
Migraine without aura 27.19 11.52 10 43549 279 50561286
Drug hypersensitivity 26.41 11.52 331 43228 250679 50310886
Malignant neoplasm progression 26.08 11.52 13 43546 68111 50493454
Vasospasm 25.62 11.52 12 43547 623 50560942
Hyperprolactinaemia 25.51 11.52 22 43537 3343 50558222
General physical health deterioration 25.21 11.52 53 43506 142381 50419184
Gastrointestinal haemorrhage 25.18 11.52 16 43543 73305 50488260
Underdose 24.46 11.52 54 43505 20224 50541341
Poor quality sleep 24.37 11.52 48 43511 16598 50544967
Cluster headache 24.37 11.52 11 43548 524 50561041
Blood creatinine increased 24.32 11.52 18 43541 76142 50485423
Pleural effusion 23.82 11.52 21 43538 81433 50480132
Injection site laceration 23.34 11.52 7 43552 101 50561464
Product use issue 22.95 11.52 60 43499 149415 50412150
Impaired healing 22.93 11.52 16 43543 69770 50491795
Synovitis 22.85 11.52 45 43514 123820 50437745
Injury 22.82 11.52 93 43466 48832 50512733
Personality disorder 22.62 11.52 23 43536 4301 50557264
Tremor 22.14 11.52 172 43387 114731 50446834
Cardiac failure congestive 22.08 11.52 24 43535 84358 50477207
Application site papules 22.02 11.52 6 43553 60 50561505
Vasoconstriction 21.95 11.52 10 43549 487 50561078
Photophobia 21.88 11.52 43 43516 14844 50546721
Multiple sclerosis 21.87 11.52 52 43507 20441 50541124
Septic shock 21.75 11.52 11 43548 57164 50504401
Rash 21.55 11.52 257 43302 437214 50124351
Palpitations 21.38 11.52 147 43412 94359 50467206
Paraesthesia oral 21.33 11.52 38 43521 12183 50549382
Stomatitis 21.23 11.52 34 43525 101310 50460255
Renal failure 21.20 11.52 37 43522 106596 50454969
Eyelid ptosis 20.56 11.52 26 43533 6161 50555404
Dependence 20.06 11.52 15 43544 1860 50559705
Neonatal respiratory distress 19.73 11.52 8 43551 292 50561273
Somnolence 19.67 11.52 212 43347 154773 50406792
Neck pain 19.53 11.52 99 43460 56968 50504597
Migraine with aura 19.51 11.52 16 43543 2269 50559296
Phonophobia 19.50 11.52 8 43551 301 50561264
Basilar migraine 19.23 11.52 5 43554 41 50561524
Irritability 19.21 11.52 61 43498 28365 50533200
Muscle spasms 18.95 11.52 178 43381 125375 50436190
Pyrexia 18.85 11.52 223 43336 379980 50181585
Narcolepsy 18.84 11.52 12 43547 1148 50560417
Sunburn 18.80 11.52 16 43543 2387 50559178
Product adhesion issue 18.79 11.52 21 43538 4371 50557194
Large intestinal ulcer haemorrhage 18.73 11.52 6 43553 109 50561456
Multiple organ dysfunction syndrome 18.68 11.52 10 43549 50327 50511238
Osteonecrosis of jaw 18.30 11.52 3 43556 32523 50529042
Spleen congestion 18.28 11.52 6 43553 118 50561447
Biliary dyskinesia 17.98 11.52 16 43543 2534 50559031
Cerebral venous thrombosis 17.89 11.52 14 43545 1857 50559708
Injection site injury 17.74 11.52 9 43550 557 50561008
Incorrect product administration duration 17.70 11.52 30 43529 9245 50552320
Decreased appetite 17.68 11.52 101 43458 200822 50360743
Thrombocytopenia 17.56 11.52 54 43505 127619 50433946
Middle insomnia 17.51 11.52 31 43528 9890 50551675
Post-traumatic stress disorder 17.43 11.52 20 43539 4283 50557282
Cough 17.32 11.52 129 43430 241135 50320430
Device use error 17.29 11.52 22 43537 5244 50556321
Blood testosterone increased 17.16 11.52 6 43553 144 50561421
Vision blurred 17.00 11.52 121 43438 78526 50483039
International normalised ratio increased 16.87 11.52 8 43551 43144 50518421
Lactic acidosis 16.83 11.52 4 43555 33351 50528214
Drug dependence 16.79 11.52 46 43513 19713 50541852
Hip arthroplasty 16.70 11.52 3 43556 30426 50531139
Subclavian artery thrombosis 16.46 11.52 6 43553 163 50561402
Drug effect less than expected 16.25 11.52 8 43551 464 50561101
Hyperacusis 16.18 11.52 13 43546 1791 50559774
Meningoradiculitis 16.14 11.52 5 43554 81 50561484
Application site dermatitis 16.13 11.52 6 43553 173 50561392
Sleep talking 15.99 11.52 10 43549 926 50560639
Memory impairment 15.95 11.52 120 43439 79240 50482325
Red blood cell sedimentation rate increased 15.93 11.52 3 43556 29413 50532152
Superior sagittal sinus thrombosis 15.85 11.52 9 43550 698 50560867
Bipolar disorder 15.84 11.52 24 43535 6733 50554832
Seizure 15.78 11.52 163 43396 117711 50443854
Neoplasm progression 15.73 11.52 3 43556 29154 50532411
Gastrooesophageal reflux disease 15.61 11.52 116 43443 76312 50485253
Major depression 15.50 11.52 24 43535 6860 50554705
Transverse sinus thrombosis 15.46 11.52 8 43551 516 50561049
Injury associated with device 15.26 11.52 16 43543 3101 50558464
Lichen planus 15.13 11.52 13 43546 1966 50559599
Cerebral venous sinus thrombosis 14.92 11.52 12 43547 1656 50559909
Hyperreflexia 14.67 11.52 20 43539 5098 50556467
Bone marrow failure 14.57 11.52 3 43556 27621 50533944
Hepatic function abnormal 14.50 11.52 5 43554 32676 50528889
Gastrointestinal disorder 14.42 11.52 38 43521 94418 50467147
Nipple pain 14.42 11.52 6 43553 234 50561331
Peripheral nerve injury 14.40 11.52 7 43552 395 50561170
Trismus 14.31 11.52 16 43543 3332 50558233
Burning sensation 14.28 11.52 77 43482 45369 50516196
Gallbladder disorder 14.25 11.52 39 43520 16703 50544862
Therapeutic response shortened 14.24 11.52 24 43535 7365 50554200
Ischaemic cerebral infarction 14.10 11.52 10 43549 1143 50560422
Pancreatic failure 14.05 11.52 9 43550 869 50560696
Potassium wasting nephropathy 14.02 11.52 4 43555 48 50561517
Melaena 14.00 11.52 3 43556 26861 50534704
Alanine aminotransferase increased 13.91 11.52 35 43524 88324 50473241
Rash maculo-papular 13.83 11.52 3 43556 26638 50534927
Multiple sclerosis relapse 13.64 11.52 73 43486 42891 50518674
Cardio-respiratory arrest 13.37 11.52 16 43543 53876 50507689
Pneumonia aspiration 13.32 11.52 5 43554 30999 50530566
Maternal exposure during pregnancy 13.16 11.52 82 43477 159696 50401869
Slow speech 13.15 11.52 10 43549 1272 50560293
Hyperhidrosis 13.10 11.52 126 43433 89300 50472265
Post viral fatigue syndrome 13.09 11.52 6 43553 296 50561269
Meningitis aseptic 13.09 11.52 17 43542 4135 50557430
Gallbladder injury 13.06 11.52 10 43549 1284 50560281
Cholestasis 12.91 11.52 3 43556 25398 50536167
Deep vein thrombosis 12.63 11.52 107 43452 73197 50488368
Sensory disturbance 12.60 11.52 30 43529 11799 50549766
Toxicity to various agents 12.38 11.52 120 43439 212379 50349186
Hepatotoxicity 12.37 11.52 4 43555 27222 50534343
Product packaging quantity issue 12.36 11.52 9 43550 1071 50560494
Blood HIV RNA increased 12.34 11.52 7 43552 542 50561023
Nasal discomfort 12.33 11.52 16 43543 3888 50557677
Influenza like illness 12.18 11.52 88 43471 57371 50504194
Chemical burn 12.08 11.52 6 43553 355 50561210
Knee arthroplasty 12.06 11.52 8 43551 35838 50525727
Respiratory disorder 11.86 11.52 6 43553 31181 50530384
Ovarian neoplasm 11.85 11.52 8 43551 844 50560721
Complement factor C4 decreased 11.85 11.52 5 43554 202 50561363
Premature delivery 11.63 11.52 3 43556 23660 50537905
Pharyngeal oedema 11.53 11.52 31 43528 13134 50548431

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Product physical issue 992.79 18.11 199 6983 1889 29565456
Product dose omission issue 243.88 18.11 195 6987 96188 29471157
Migraine 128.65 18.11 62 7120 12368 29554977
Product quality issue 122.66 18.11 65 7117 15830 29551515
Device deployment issue 98.02 18.11 18 7164 100 29567245
Headache 79.29 18.11 147 7035 173860 29393485
Arteriospasm coronary 71.69 18.11 26 7156 2539 29564806
Device malfunction 63.36 18.11 34 7148 8473 29558872
Device issue 57.68 18.11 31 7151 7749 29559596
Serotonin syndrome 51.76 18.11 39 7143 17473 29549872
Throat tightness 49.08 18.11 27 7155 7064 29560281
IIIrd nerve paresis 44.63 18.11 9 7173 87 29567258
Accidental exposure to product 41.08 18.11 28 7154 10725 29556620
Hyperhidrosis 37.71 18.11 61 7121 64479 29502866
Injection site pain 36.25 18.11 42 7140 32404 29534941
Cluster headache 34.52 18.11 10 7172 476 29566869
Application site pain 32.43 18.11 13 7169 1666 29565679
Medication overuse headache 31.18 18.11 7 7175 117 29567228
Myofascial pain syndrome 29.41 18.11 8 7174 302 29567043
Acute kidney injury 29.23 18.11 14 7168 265253 29302092
Needle issue 27.46 18.11 16 7166 4667 29562678
Application site burn 27.44 18.11 7 7175 205 29567140
Xanthelasma 27.03 18.11 6 7176 95 29567250
Gastrointestinal tract irritation 26.82 18.11 7 7175 225 29567120
Anophthalmos 26.52 18.11 4 7178 4 29567341
Congenital genital malformation male 24.90 18.11 4 7178 8 29567337
Facial pain 24.90 18.11 11 7171 1794 29565551
Foetal malnutrition 23.96 18.11 5 7177 58 29567287
Burns second degree 23.77 18.11 7 7175 353 29566992
Autonomic dysreflexia 23.16 18.11 5 7177 69 29567276
Death 21.71 18.11 31 7151 342053 29225292
Drug ineffective 21.49 18.11 156 7026 363014 29204331
Capillaritis 21.28 18.11 5 7177 103 29567242
Foetal exposure during pregnancy 21.12 18.11 33 7149 33834 29533511
Muscle tightness 20.73 18.11 13 7169 4325 29563020
Electrocardiogram ST segment elevation 20.32 18.11 13 7169 4479 29562866
Craniosynostosis 20.29 18.11 6 7176 307 29567038
Application site erythema 20.28 18.11 10 7172 2089 29565256
Irritable bowel syndrome 19.94 18.11 11 7171 2890 29564455
Injection site haemorrhage 19.03 18.11 16 7166 8370 29558975
Paraesthesia 18.99 18.11 41 7141 53804 29513541
Tobacco abuse 18.93 18.11 6 7176 388 29566957
Anxiety 18.51 18.11 54 7128 85311 29482034
Aphasia 18.39 18.11 23 7159 19175 29548170
Insomnia 18.15 18.11 55 7127 88706 29478639

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Product physical issue 1348.01 12.34 329 37679 3120 64457604
Migraine 527.96 12.34 373 37635 62304 64398420
Application site erythema 404.71 12.34 138 37870 4551 64456173
Product dose omission issue 321.94 12.34 479 37529 194268 64266456
Application site burn 285.93 12.34 71 37937 725 64459999
Application site pain 238.59 12.34 91 37917 4157 64456567
Product quality issue 227 12.34 167 37841 29632 64431092
Application site discolouration 193.71 12.34 51 37957 669 64460055
Device malfunction 186.59 12.34 121 37887 17512 64443212
Application site paraesthesia 181.44 12.34 32 37976 37 64460687
Headache 159.65 12.34 675 37333 528792 63931932
Arteriospasm coronary 151.90 12.34 71 37937 5394 64455330
Accidental exposure to product 147.18 12.34 123 37885 26241 64434483
Medication overuse headache 124.81 12.34 36 37972 674 64460050
IIIrd nerve paresis 117.60 12.34 26 37982 151 64460573
Throat tightness 116.91 12.34 102 37906 23058 64437666
Acute kidney injury 114.74 12.34 61 37947 449179 64011545
Colitis ischaemic 110.83 12.34 79 37929 13335 64447389
Anxiety 103.71 12.34 308 37700 202341 64258383
Application site pruritus 101.52 12.34 47 37961 3492 64457232
Application site irritation 100.29 12.34 37 37971 1539 64459185
Application site warmth 100.21 12.34 23 37985 162 64460562
Device deployment issue 98.49 12.34 43 37965 2783 64457941
Paraesthesia 93.50 12.34 229 37779 134293 64326431
Death 92.54 12.34 89 37919 482616 63978108
Application site rash 89.10 12.34 36 37972 1918 64458806
Application site urticaria 89 12.34 22 37986 220 64460504
Reversible cerebral vasoconstriction syndrome 86.08 12.34 37 37971 2305 64458419
Device issue 80.28 12.34 82 37926 22566 64438158
Serotonin syndrome 80.05 12.34 107 37901 39175 64421549
Wrong technique in product usage process 79.94 12.34 140 37868 64834 64395890
Anaemia 77.08 12.34 66 37942 378614 64082110
Application site swelling 71.86 12.34 23 37985 619 64460105
Application site scar 68.24 12.34 17 37991 176 64460548
Cerebral vasoconstriction 67.98 12.34 26 37982 1196 64459528
Muscle twitching 64.11 12.34 67 37941 18931 64441793
Dizziness 62.27 12.34 450 37558 429713 64031011
Depression 60.66 12.34 241 37767 183050 64277674
Endometriosis 58.76 12.34 30 37978 2762 64457962
Emotional distress 58.40 12.34 88 37920 35950 64424774
Cardiac failure 56.68 12.34 6 38002 132367 64328357
Chest discomfort 56.05 12.34 173 37835 115933 64344791
Application site vesicles 55.65 12.34 23 37985 1299 64459425
Febrile neutropenia 54.80 12.34 21 37987 187636 64273088
Injection site pain 54.71 12.34 167 37841 111241 64349483
Post-traumatic neck syndrome 53.75 12.34 25 37983 1877 64458847
Coronary artery dissection 52.92 12.34 20 37988 890 64459834
Pneumonia 52.27 12.34 163 37845 559413 63901311
Pituitary tumour benign 52.24 12.34 26 37982 2267 64458457
Cholecystitis chronic 51.13 12.34 43 37965 9244 64451480
Nausea 48.54 12.34 689 37319 785111 63675613
Soft tissue injury 48.53 12.34 22 37986 1557 64459167
Muscle tightness 48.29 12.34 45 37963 11070 64449654
Drug ineffective 48.09 12.34 727 37281 839520 63621204
Injection site haemorrhage 47.73 12.34 65 37943 24213 64436511
Chest pain 47.11 12.34 268 37740 235712 64225012
Sepsis 46.98 12.34 40 37968 230301 64230423
Cluster headache 46.92 12.34 18 37990 835 64459889
Hypoaesthesia 46.88 12.34 184 37824 138924 64321800
Concussion 46.29 12.34 38 37970 7900 64452824
Hot flush 46.04 12.34 91 37917 46144 64414580
Application site exfoliation 46.03 12.34 14 37994 317 64460407
Neutropenia 46.03 12.34 44 37964 239580 64221144
Tension headache 45.36 12.34 27 37981 3356 64457368
Renal infarct 45.27 12.34 24 37984 2387 64458337
Renal impairment 44.92 12.34 12 37996 135005 64325719
Application site dryness 44.59 12.34 12 37996 172 64460552
Hostility 44.38 12.34 23 37985 2184 64458540
Renal failure 44.35 12.34 26 37982 181662 64279062
Incorrect route of product administration 43.73 12.34 61 37947 23237 64437487
Libido increased 42.87 12.34 21 37987 1769 64458955
Product substitution issue 41.62 12.34 52 37956 17809 64442915
Sternal fracture 41.16 12.34 22 37986 2225 64458499
Disease progression 41.12 12.34 16 37992 141664 64319060
Device power source issue 40.99 12.34 16 37992 778 64459946
Hyperkalaemia 39.86 12.34 6 38002 101123 64359601
Hypotension 38.39 12.34 107 37901 380867 64079857
Interstitial lung disease 38.06 12.34 6 38002 97726 64362998
Pancytopenia 37.16 12.34 19 37989 143290 64317434
Atrial fibrillation 37.02 12.34 28 37980 171061 64289663
Drug specific antibody 36.94 12.34 20 37988 2075 64458649
Platelet count decreased 36.86 12.34 27 37981 167684 64293040
Infusion related reaction 36.77 12.34 26 37982 164441 64296283
Injection site bruising 35.50 12.34 71 37937 36302 64424422
Injury 35.38 12.34 92 37916 55900 64404824
Clonus 35.29 12.34 29 37979 6038 64454686
Hyponatraemia 35.12 12.34 22 37986 148317 64312407
Angle closure glaucoma 35.09 12.34 21 37987 2636 64458088
Drug hypersensitivity 35.00 12.34 250 37758 237565 64223159
Feeling abnormal 34.44 12.34 163 37845 133439 64327285
Multiple organ dysfunction syndrome 33.76 12.34 9 37999 101404 64359320
Application site inflammation 33.66 12.34 12 37996 452 64460272
Thrombocytopenia 33.48 12.34 50 37958 223751 64236973
Septic shock 32.12 12.34 11 37997 105426 64355298
Suicidal ideation 31.95 12.34 99 37909 66443 64394281
Pain 31.16 12.34 478 37530 553033 63907691
Pharyngeal swelling 31.14 12.34 26 37982 5533 64455191
Palpitations 31.07 12.34 133 37875 104355 64356369
Photophobia 30.57 12.34 44 37964 17249 64443475
Vision blurred 30.03 12.34 119 37889 90197 64370527
Application site scab 29.75 12.34 9 37999 200 64460524
Haemoglobin decreased 29.74 12.34 43 37965 195020 64265704
Treatment failure 29.53 12.34 16 37992 116800 64343924
Nightmare 29.47 12.34 48 37960 20945 64439779
Expired product administered 29.47 12.34 26 37982 5961 64454763
Gastrointestinal haemorrhage 29.46 12.34 21 37987 132291 64328433
Transient global amnesia 29.06 12.34 12 37996 676 64460048
Blood creatinine increased 28.38 12.34 23 37985 135759 64324965
Pleural effusion 28.30 12.34 20 37988 126539 64334185
Application site bruise 28.20 12.34 9 37999 240 64460484
Subclavian artery thrombosis 27.89 12.34 6 38002 30 64460694
Malignant neoplasm progression 27.75 12.34 16 37992 112855 64347869
Secondary adrenocortical insufficiency 27.05 12.34 17 37991 2328 64458396
Hyperprolactinaemia 26.99 12.34 21 37987 4044 64456680
Off label use 26.49 12.34 242 37766 632564 63828160
Pyrexia 26.36 12.34 207 37801 558437 63902287
Personality disorder 26.32 12.34 22 37986 4689 64456035
Product adhesion issue 26.31 12.34 17 37991 2442 64458282
Product leakage 26.19 12.34 11 37997 647 64460077
Device leakage 25.85 12.34 28 37980 8238 64452486
Vasospasm 25.49 12.34 12 37996 926 64459798
Therapeutic response unexpected 25.41 12.34 40 37968 16961 64443763
Lower respiratory tract infection 25.35 12.34 12 37996 94602 64366122
Application site reaction 25.31 12.34 11 37997 704 64460020
Application site discomfort 25.19 12.34 9 37999 341 64460383
Cardiac failure congestive 25.02 12.34 24 37984 130556 64330168
Hyperhidrosis 24.97 12.34 142 37866 124778 64335946
Incorrect dose administered by device 24.71 12.34 20 37988 4077 64456647
Somnambulism 24.65 12.34 22 37986 5119 64455605
Migraine without aura 24.56 12.34 8 38000 228 64460496
Temperature intolerance 24.15 12.34 27 37981 8228 64452496
Respiratory failure 24.10 12.34 36 37972 161147 64299577
Insomnia 24.08 12.34 199 37809 197637 64263087
Cerebral venous thrombosis 23.99 12.34 16 37992 2425 64458299
Muscle spasms 23.55 12.34 153 37855 140870 64319854
Dysgeusia 23.52 12.34 71 37937 46976 64413748
Poor quality sleep 23.50 12.34 41 37967 18910 64441814
Electrocardiogram ST segment elevation 23.42 12.34 25 37983 7234 64453490
Drug dependence 23.41 12.34 57 37951 33255 64427469
Renal tubular acidosis 23.36 12.34 17 37991 2962 64457762
Vasoconstriction 23.34 12.34 10 37998 618 64460106
Memory impairment 23.15 12.34 106 37902 85576 64375148
Glossodynia 22.98 12.34 5 38003 64691 64396033
Paraesthesia oral 22.61 12.34 33 37975 13098 64447626
Infection 22.48 12.34 47 37961 184833 64275891
Phonophobia 22.42 12.34 9 37999 471 64460253
Neck pain 22.02 12.34 83 37925 61450 64399274
Wound 21.59 12.34 9 37999 76468 64384256
Gallbladder disorder 21.32 12.34 37 37971 16993 64443731
Head discomfort 20.75 12.34 30 37978 11804 64448920
Myofascial pain syndrome 20.65 12.34 13 37995 1785 64458939
Product complaint 20.52 12.34 30 37978 11924 64448800
Therapeutic product effect incomplete 20.26 12.34 117 37891 103365 64357359
Middle insomnia 20.23 12.34 31 37977 12846 64447878
Tremor 20.17 12.34 153 37855 148077 64312647
Migraine with aura 19.98 12.34 14 37994 2298 64458426
Pharyngeal oedema 19.78 12.34 34 37974 15497 64445227
International normalised ratio increased 19.78 12.34 11 37997 79156 64381568
Application site papules 19.71 12.34 5 38003 56 64460668
Diarrhoea 19.59 12.34 304 37704 722400 63738324
Burns second degree 19.49 12.34 10 37998 930 64459794
Basilar migraine 19.47 12.34 5 38003 59 64460665
Burning sensation 19.47 12.34 69 37939 49595 64411129
Decreased appetite 19.08 12.34 93 37915 281196 64179528
Oxygen saturation decreased 19.06 12.34 21 37987 107155 64353569
Meningitis aseptic 18.96 12.34 20 37988 5710 64455014
Irritability 18.88 12.34 56 37952 36690 64424034
Flushing 18.85 12.34 94 37914 78554 64382170
Epistaxis 18.84 12.34 18 37990 98113 64362611
Xanthelasma 18.80 12.34 6 38002 160 64460564
Hyperreflexia 18.58 12.34 22 37986 7126 64453598
Dependence 18.51 12.34 13 37995 2142 64458582
Facial pain 18.41 12.34 23 37985 7872 64452852
Drug effect less than expected 18.30 12.34 8 38000 519 64460205
Pre-existing condition improved 18.26 12.34 18 37990 4744 64455980
Post-traumatic stress disorder 18.22 12.34 17 37991 4188 64456536
Aphasia 17.93 12.34 59 37949 40847 64419877
Peripheral coldness 17.65 12.34 30 37978 13554 64447170
Blood bilirubin increased 17.53 12.34 6 38002 57547 64403177
Ovarian neoplasm 17.53 12.34 8 38000 575 64460149
Biliary dyskinesia 17.39 12.34 13 37995 2359 64458365
Loss of consciousness 17.38 12.34 148 37860 148217 64312507
Visual impairment 17.37 12.34 88 37920 73989 64386735
Hyperacusis 17.33 12.34 12 37996 1933 64458791
Transverse sinus thrombosis 17.06 12.34 8 38000 612 64460112
Application site erosion 17.01 12.34 6 38002 219 64460505
Gastrooesophageal reflux disease 16.93 12.34 95 37913 83048 64377676
Burns third degree 16.82 12.34 7 38001 402 64460322
Bone marrow failure 16.45 12.34 4 38004 47948 64412776
Superior sagittal sinus thrombosis 16.33 12.34 9 37999 967 64459757
Withdrawal syndrome 16.30 12.34 40 37968 23452 64437272
Lactic acidosis 16.12 12.34 8 38000 61402 64399322
Injection site laceration 16.08 12.34 5 38003 122 64460602
Multiple sclerosis relapse 15.99 12.34 57 37951 41078 64419646
Rheumatoid arthritis 15.88 12.34 47 37961 164247 64296477
Injection site erythema 15.83 12.34 83 37925 70717 64390007
Aspartate aminotransferase increased 15.81 12.34 29 37979 119759 64340965
Haematuria 15.69 12.34 8 38000 60463 64400261
Hypoglycaemia 15.56 12.34 18 37990 89874 64370850
Meningoradiculitis 15.50 12.34 5 38003 138 64460586
Cerebral venous sinus thrombosis 15.49 12.34 11 37997 1844 64458880
Sunburn 15.47 12.34 14 37994 3318 64457406
Large intestinal ulcer haemorrhage 15.40 12.34 6 38002 290 64460434
General physical health deterioration 15.40 12.34 65 37943 204360 64256364
Pancreatic failure 15.39 12.34 10 37998 1450 64459274
Blood pressure systolic increased 15.34 12.34 5 38003 49448 64411276
Post viral fatigue syndrome 15.25 12.34 6 38002 298 64460426
Systemic lupus erythematosus 15.18 12.34 14 37994 77598 64383126
Toxicity to various agents 15.17 12.34 139 37869 363374 64097350
Deep vein thrombosis 15.11 12.34 110 37898 105072 64355652
Gallbladder injury 14.97 12.34 9 37999 1139 64459585
Neoplasm progression 14.89 12.34 3 38005 40961 64419763
Gastrointestinal tract irritation 14.88 12.34 7 38001 539 64460185
Incorrect disposal of product 14.73 12.34 8 38000 835 64459889
Torsade de pointes 14.73 12.34 32 37976 17331 64443393
Cardio-respiratory arrest 14.68 12.34 22 37986 98371 64362353
Incorrect product administration duration 14.64 12.34 23 37985 9735 64450989
Device difficult to use 14.57 12.34 23 37985 9775 64450949
Vertigo 14.47 12.34 71 37937 58940 64401784
Impaired healing 14.26 12.34 9 37999 60464 64400260
Needle issue 14.11 12.34 22 37986 9250 64451474
Pericardial effusion 14.01 12.34 3 38005 39251 64421473
Major depression 13.98 12.34 20 37988 7796 64452928
Therapeutic response shortened 13.93 12.34 23 37985 10147 64450577
Hormone level abnormal 13.92 12.34 10 37998 1707 64459017
Peripheral nerve injury 13.87 12.34 7 38001 629 64460095
Eyelid ptosis 13.67 12.34 22 37986 9503 64451221
Injection site urticaria 13.62 12.34 24 37984 11157 64449567
Haemorrhage 13.61 12.34 16 37992 79335 64381389
Bradycardia 13.58 12.34 31 37977 118188 64342536
Contraindicated product administered 13.45 12.34 27 37981 107802 64352922
Nasal oedema 13.40 12.34 8 38000 1000 64459724
Eye pain 13.32 12.34 45 37963 31580 64429144
Alanine aminotransferase increased 13.27 12.34 40 37968 138991 64321733
Lichen planus 13.27 12.34 11 37997 2317 64458407
Product dispensing error 13.21 12.34 24 37984 11426 64449298
Complement factor C4 decreased 13.01 12.34 5 38003 233 64460491
Cytomegalovirus infection 12.96 12.34 3 38005 37196 64423528
Underdose 12.92 12.34 39 37969 25790 64434934
Choking sensation 12.89 12.34 13 37995 3522 64457202
Arthropathy 12.89 12.34 33 37975 120934 64339790
Capillaritis 12.89 12.34 5 38003 239 64460485
Panic attack 12.79 12.34 34 37974 20919 64439805
Neutrophil count decreased 12.78 12.34 16 37992 77180 64383544
Body temperature increased 12.74 12.34 49 37959 36617 64424107
Trismus 12.60 12.34 15 37993 4886 64455838
Seizure 12.56 12.34 152 37856 166740 64293984
Hepatotoxicity 12.46 12.34 4 38004 39958 64420766
Slow speech 12.40 12.34 10 37998 2027 64458697

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC N02CC01 NERVOUS SYSTEM
ANALGESICS
ANTIMIGRAINE PREPARATIONS
Selective serotonin (5HT1) agonists
CHEBI has role CHEBI:35941 serotonin agonists
FDA MoA N0000175763 Serotonin 1b Receptor Agonists
FDA MoA N0000175764 Serotonin 1d Receptor Agonists
FDA EPC N0000175765 Serotonin-1b and Serotonin-1d Receptor Agonist
MeSH PA D002317 Cardiovascular Agents
MeSH PA D018377 Neurotransmitter Agents
MeSH PA D058825 Serotonin 5-HT1 Receptor Agonists
MeSH PA D018490 Serotonin Agents
MeSH PA D017366 Serotonin Receptor Agonists
MeSH PA D014662 Vasoconstrictor Agents

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Migraine indication 37796009 DOID:6364
Cluster headache syndrome indication 193031009
Tachyarrhythmia contraindication 6285003
Alcoholism contraindication 7200002
Hypercholesterolemia contraindication 13644009
Myocardial infarction contraindication 22298006 DOID:5844
Hypertensive disorder contraindication 38341003 DOID:10763
Gastrointestinal ulcer contraindication 40845000
Body fluid retention contraindication 43498006
Chronic heart failure contraindication 48447003
Disorder of cardiovascular system contraindication 49601007 DOID:1287
Hemiplegic migraine contraindication 59292006
Hepatic failure contraindication 59927004
Blood coagulation disorder contraindication 64779008 DOID:1247
Diabetes mellitus contraindication 73211009 DOID:9351
Gastrointestinal hemorrhage contraindication 74474003
Vascular insufficiency of intestine contraindication 82196007
Epilepsy contraindication 84757009 DOID:1826
Prinzmetal angina contraindication 87343002
Kidney disease contraindication 90708001 DOID:557
Liver function tests abnormal contraindication 166603001
Angina pectoris contraindication 194828000
Cerebrovascular accident contraindication 230690007
Coronary artery bypass graft contraindication 232717009
Disease of liver contraindication 235856003 DOID:409
Transient ischemic attack contraindication 266257000 DOID:224
Esophageal dysmotility contraindication 266434009 DOID:9192
Edema contraindication 267038008
Anemia contraindication 271737000 DOID:2355
Cerebral ischemia contraindication 287731003
Pregnancy, function contraindication 289908002
Thromboembolic disorder contraindication 371039008
Serotonin syndrome contraindication 371089000
Cardiovascular event risk contraindication 395112001
Peripheral vascular disease contraindication 400047006
Disorder of coronary artery contraindication 414024009
Myocardial ischemia contraindication 414795007 DOID:3393
Obesity contraindication 414916001 DOID:9970
Hypertensive urgency contraindication 443482000
Smokes tobacco daily contraindication 449868002




๐Ÿถ Veterinary Drug Use

None

๐Ÿถ Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 11.23 acidic
pKa2 13.42 acidic
pKa3 8.28 Basic

Orange Book patent data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
EQ 11MG BASE ONZETRA XSAIL CURRAX N206099 Jan. 27, 2016 RX POWDER NASAL 8327844 Oct. 3, 2023 METHOD OF DRUG DELIVERY VIA THE NASAL CAVITY
EQ 11MG BASE ONZETRA XSAIL CURRAX N206099 Jan. 27, 2016 RX POWDER NASAL 7975690 Aug. 18, 2025 METHOD OF DRUG DELIVERY VIA THE NASAL CAVITY
EQ 11MG BASE ONZETRA XSAIL CURRAX N206099 Jan. 27, 2016 RX POWDER NASAL 8590530 Sept. 15, 2025 METHOD OF DRUG DELIVERY VIA THE NASAL CAVITY
500MG;EQ 85MG BASE TREXIMET CURRAX N021926 April 15, 2008 RX TABLET ORAL 7332183 Oct. 2, 2025 TREATMENT OF MIGRAINE
60MG;EQ 10MG BASE TREXIMET CURRAX N021926 May 14, 2015 DISCN TABLET ORAL 7332183 Oct. 2, 2025 ACUTE TREATMENT OF MIGRAINE
10MG/SPRAY TOSYMRA UPSHER SMITH LABS N210884 Jan. 25, 2019 RX SPRAY NASAL 8440631 May 9, 2026 ACUTE TREATMENT OF MIGRAINE
EQ 11MG BASE ONZETRA XSAIL CURRAX N206099 Jan. 27, 2016 RX POWDER NASAL 10124132 March 6, 2027 ACUTE TREATMENT OF MIGRAINE
EQ 11MG BASE ONZETRA XSAIL CURRAX N206099 Jan. 27, 2016 RX POWDER NASAL 10124132 March 6, 2027 ACUTE TREATMENT OF MIGRAINE BY DELIVERING A POWDERED SUBSTANCE COMPRISING SUMATRIPTAN VIA A BREATH-POWERED DELIVERY DEVICE
EQ 11MG BASE ONZETRA XSAIL CURRAX N206099 Jan. 27, 2016 RX POWDER NASAL 10124132 March 6, 2027 TREATMENT OF MIGRAINE VIA DELIVERY OF SUMATRIPTAN VIA THE NASAL CAVITY
EQ 6.5MG BASE/4HR ZECUITY TEVA BRANDED PHARM N202278 Jan. 17, 2013 DISCN SYSTEM IONTOPHORESIS 7973058 April 12, 2027 METHOD FOR TREATING ACUTE MIGRAINE IN ADULTS, WITH OR WITHOUT AURA, COMPRISING IONTOPHORETIC TRANSDERMAL DELIVERY OF SUMATRIPTAN OR A SALT THEREOF
EQ 6.5MG BASE/4HR ZECUITY TEVA BRANDED PHARM N202278 Jan. 17, 2013 DISCN SYSTEM IONTOPHORESIS 8155737 April 12, 2027 METHOD FOR TREATING ACUTE MIGRAINE IN ADULTS, WITH OR WITHOUT AURA, COMPRISING IONTOPHORETIC TRANSDERMAL DELIVERY OF SUMATRIPTAN OR A SALT THEREOF
EQ 6.5MG BASE/4HR ZECUITY TEVA BRANDED PHARM N202278 Jan. 17, 2013 DISCN SYSTEM IONTOPHORESIS 8470853 April 12, 2027 METHOD FOR TREATING ACUTE MIGRAINE IN ADULTS, WITH OR WITHOUT AURA, COMPRISING IONTOPHORETIC TRANSDERMAL DELIVERY OF SUMATRIPTAN OR A SALT THEREOF
EQ 6.5MG BASE/4HR ZECUITY TEVA BRANDED PHARM N202278 Jan. 17, 2013 DISCN SYSTEM IONTOPHORESIS 9427578 April 12, 2027 METHOD FOR TREATING ACUTE MIGRAINE IN ADULTS, WITH OR WITHOUT AURA, COMPRISING IONTOPHORETIC TRANSDERMAL DELIVERY OF SUMATRIPTAN OR A SALT THEREOF
EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML) ALSUMA MERIDIAN MEDCL N022377 June 29, 2010 DISCN INJECTABLE SUBCUTANEOUS 7811254 Aug. 26, 2027 ACUTE TREATMENT OF MIGRAINE ATTACKS, WITH OR WITHOUT AURA, AND THE TREATMENT OF CLUSTER HEADACHE EPISODES
EQ 11MG BASE ONZETRA XSAIL CURRAX N206099 Jan. 27, 2016 RX POWDER NASAL 8875704 April 7, 2028 METHOD OF DRUG DELIVERY VIA THE NASAL CAVITY
EQ 6.5MG BASE/4HR ZECUITY TEVA BRANDED PHARM N202278 Jan. 17, 2013 DISCN SYSTEM IONTOPHORESIS 8366600 April 21, 2029 METHOD FOR TREATING ACUTE MIGRAINE IN ADULTS, WITH OR WITHOUT AURA, COMPRISING IONTOPHORETIC TRANSDERMAL DELIVERY OF SUMATRIPTAN OR A SALT THEREOF, USING A FLOWABLE HYDROGEL FORMULATION
EQ 11MG BASE ONZETRA XSAIL CURRAX N206099 Jan. 27, 2016 RX POWDER NASAL 10076615 July 30, 2029 ACUTE TREATMENT OF MIGRAINE BY DELIVERING A POWDERED SUBSTANCE COMPRISING SUMATRIPTAN VIA A BREATH-POWERED DELIVERY DEVICE
EQ 11MG BASE ONZETRA XSAIL CURRAX N206099 Jan. 27, 2016 RX POWDER NASAL 10076615 July 30, 2029 METHOD OF DELIVERING SUMATRIPTAN TO A NASAL CAVITY
EQ 11MG BASE ONZETRA XSAIL CURRAX N206099 Jan. 27, 2016 RX POWDER NASAL 10076615 July 30, 2029 TREATMENT OF MIGRAINE VIA DELIVERY OF SUMATRIPTAN VIA THE NASAL CAVITY
10MG/SPRAY TOSYMRA UPSHER SMITH LABS N210884 Jan. 25, 2019 RX SPRAY NASAL 10603305 June 16, 2030 ACUTE TREATMENT OF MIGRAINE
10MG/SPRAY TOSYMRA UPSHER SMITH LABS N210884 Jan. 25, 2019 RX SPRAY NASAL 11337962 June 16, 2030 ACUTE TREATMENT OF MIGRAINE
10MG/SPRAY TOSYMRA UPSHER SMITH LABS N210884 Jan. 25, 2019 RX SPRAY NASAL 9610280 June 16, 2030 ACUTE TREATMENT OF MIGRAINE
10MG/SPRAY TOSYMRA UPSHER SMITH LABS N210884 Jan. 25, 2019 RX SPRAY NASAL 9974770 June 16, 2030 ACUTE TREATMENT OF MIGRAINE
EQ 11MG BASE ONZETRA XSAIL CURRAX N206099 Jan. 27, 2016 RX POWDER NASAL 9649456 Oct. 21, 2030 ACUTE TREATMENT OF MIGRAINE
EQ 11MG BASE ONZETRA XSAIL CURRAX N206099 Jan. 27, 2016 RX POWDER NASAL 9649456 Oct. 21, 2030 ACUTE TREATMENT OF MIGRAINE BY DELIVERING A POWDERED SUBSTANCE COMPRISING SUMATRIPTAN VIA A BREATH-POWERED DELIVERY DEVICE
EQ 11MG BASE ONZETRA XSAIL CURRAX N206099 Jan. 27, 2016 RX POWDER NASAL 9649456 Oct. 21, 2030 TREATMENT OF MIGRAINE VIA DELIVERY OF SUMATRIPTAN VIA THE NASAL CAVITY
EQ 6.5MG BASE/4HR ZECUITY TEVA BRANDED PHARM N202278 Jan. 17, 2013 DISCN SYSTEM IONTOPHORESIS 8983594 Nov. 19, 2030 METHOD FOR TREATING ACUTE MIGRAINE IN ADULTS, WITH OR WITHOUT AURA, COMPRISING IONTOPHORETIC TRANSDERMAL DELIVERY OF SUMATRIPTAN OR A SALT THEREOF
10MG/SPRAY TOSYMRA UPSHER SMITH LABS N210884 Jan. 25, 2019 RX SPRAY NASAL 9211282 July 19, 2031 ACUTE TREATMENT OF MIGRAINE
EQ 6.5MG BASE/4HR ZECUITY TEVA BRANDED PHARM N202278 Jan. 17, 2013 DISCN SYSTEM IONTOPHORESIS 9327114 Oct. 8, 2032 METHOD FOR TREATING ACUTE MIGRAINE IN ADULTS, WITH OR WITHOUT AURA, COMPRISING IONTOPHORETIC TRANSDERMAL DELIVERY OF SUMATRIPTAN OR A SALT THEREOF
EQ 11MG BASE ONZETRA XSAIL CURRAX N206099 Jan. 27, 2016 RX POWDER NASAL 10478574 Nov. 4, 2033 METHOD OF DELIVERING SUMATRIPTAN TO A NASAL CAVITY
EQ 3MG BASE/0.5ML (EQ 3MG BASE/0.5ML) ZEMBRACE SYMTOUCH UPSHER SMITH LABS N208223 Jan. 28, 2016 RX SOLUTION SUBCUTANEOUS 10537554 Jan. 29, 2036 TREATMENT OF MIGRAINE

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
5-hydroxytryptamine receptor 1D GPCR AGONIST Ki 8.92 CHEMBL CHEMBL
5-hydroxytryptamine receptor 1B GPCR AGONIST Ki 8.26 CHEMBL CHEMBL
5-hydroxytryptamine receptor 2C GPCR IC50 8.14 CHEMBL
5-hydroxytryptamine receptor 6 GPCR ANTAGONIST Ki 5.60 IUPHAR
5-hydroxytryptamine receptor 7 GPCR ANTAGONIST Ki 6 IUPHAR
5-hydroxytryptamine receptor 3A Ion channel IC50 8.03 CHEMBL
5-hydroxytryptamine receptor 5A GPCR IC50 6.30 CHEMBL
5-hydroxytryptamine receptor 1F GPCR Ki 7.59 CHEMBL
5-hydroxytryptamine receptor 1E GPCR IC50 5.26 CHEMBL
Multidrug and toxin extrusion protein 1 Transporter IC50 5.17 CHEMBL
5-hydroxytryptamine receptor 1A GPCR Ki 6.64 CHEMBL
5-hydroxytryptamine receptor 2A GPCR Ki 6.42 CHEMBL
5-hydroxytryptamine receptor 1B GPCR Ki 7.64 CHEMBL
5-hydroxytryptamine receptor 1A GPCR IC50 6.19 CHEMBL
5-hydroxytryptamine receptor 7 GPCR ANTAGONIST Ki 6.60 IUPHAR
5-hydroxytryptamine receptor 1D GPCR IC50 7.70 CHEMBL
5-hydroxytryptamine receptor 1A GPCR IC50 6.35 CHEMBL
5-hydroxytryptamine receptor 1D GPCR IC50 7.21 CHEMBL
5-hydroxytryptamine receptor 6 GPCR ANTAGONIST Ki 5.20 IUPHAR
5-hydroxytryptamine receptor 1B GPCR Ki 8.19 CHEMBL
5-hydroxytryptamine 1D receptor Unclassified IC50 7.23 CHEMBL
5-hydroxytryptamine receptor 5A GPCR AGONIST Ki 4.80 IUPHAR

External reference:

IDSource
4021050 VUID
N0000148514 NUI
D00451 KEGG_DRUG
103628-48-4 SECONDARY_CAS_RN
4020790 VANDF
4021050 VANDF
C0075632 UMLSCUI
CHEBI:10650 CHEBI
CHEMBL128 ChEMBL_ID
DB00669 DRUGBANK_ID
CHEMBL1201150 ChEMBL_ID
D018170 MESH_DESCRIPTOR_UI
5358 PUBCHEM_CID
54 IUPHAR_LIGAND_ID
6125 INN_ID
8R78F6L9VO UNII
37418 RXNORM
158892 MMSL
166806 MMSL
25268 MMSL
31925 MMSL
5536 MMSL
d03160 MMSL
004044 NDDF
004045 NDDF
322822007 SNOMEDCT_US
395892000 SNOMEDCT_US
96215002 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Sumatriptan HUMAN PRESCRIPTION DRUG LABEL 1 0093-2013 INJECTION 4 mg SUBCUTANEOUS ANDA 28 sections
Sumatriptan HUMAN PRESCRIPTION DRUG LABEL 1 0093-2014 INJECTION 6 mg SUBCUTANEOUS ANDA 28 sections
SUMATRIPTAN HUMAN PRESCRIPTION DRUG LABEL 1 0143-9638 INJECTION 6 mg SUBCUTANEOUS ANDA 27 sections
IMITREX HUMAN PRESCRIPTION DRUG LABEL 1 0173-0478 INJECTION 6 mg SUBCUTANEOUS NDA 28 sections
IMITREX HUMAN PRESCRIPTION DRUG LABEL 1 0173-0479 INJECTION 6 mg SUBCUTANEOUS NDA 28 sections
IMITREX HUMAN PRESCRIPTION DRUG LABEL 1 0173-0523 SPRAY 20 mg NASAL NDA 27 sections
IMITREX HUMAN PRESCRIPTION DRUG LABEL 1 0173-0524 SPRAY 5 mg NASAL NDA 27 sections
IMITREX HUMAN PRESCRIPTION DRUG LABEL 1 0173-0735 TABLET, FILM COATED 25 mg ORAL NDA 27 sections
IMITREX HUMAN PRESCRIPTION DRUG LABEL 1 0173-0736 TABLET, FILM COATED 50 mg ORAL NDA 27 sections
IMITREX HUMAN PRESCRIPTION DRUG LABEL 1 0173-0737 TABLET, FILM COATED 100 mg ORAL NDA 27 sections
IMITREX HUMAN PRESCRIPTION DRUG LABEL 1 0173-0739 INJECTION 4 mg SUBCUTANEOUS NDA 28 sections
ZEMBRACE SYMTOUCH HUMAN PRESCRIPTION DRUG LABEL 1 0245-0809 INJECTION, SOLUTION 3 mg SUBCUTANEOUS NDA 31 sections
TOSYMRA HUMAN PRESCRIPTION DRUG LABEL 1 0245-0812 SPRAY 10 mg NASAL NDA 31 sections
Sumatriptan Succinate HUMAN PRESCRIPTION DRUG LABEL 1 0378-5630 TABLET, FILM COATED 25 mg ORAL ANDA 28 sections
Sumatriptan Succinate HUMAN PRESCRIPTION DRUG LABEL 1 0378-5631 TABLET, FILM COATED 50 mg ORAL ANDA 28 sections
Sumatriptan Succinate HUMAN PRESCRIPTION DRUG LABEL 1 0378-5632 TABLET, FILM COATED 100 mg ORAL ANDA 28 sections
Sumatriptan HUMAN PRESCRIPTION DRUG LABEL 1 0527-1818 SPRAY 5 mg NASAL ANDA 28 sections
Sumatriptan HUMAN PRESCRIPTION DRUG LABEL 1 0527-1859 SPRAY 20 mg NASAL ANDA 28 sections
Sumatriptan Succinate HUMAN PRESCRIPTION DRUG LABEL 1 16590-300 TABLET, FILM COATED 100 mg ORAL NDA 13 sections
SUMATRIPTAN SUCCINATE HUMAN PRESCRIPTION DRUG LABEL 1 16590-408 TABLET 50 mg ORAL ANDA 27 sections
SUMATRIPTAN SUCCINATE HUMAN PRESCRIPTION DRUG LABEL 1 16590-950 TABLET 25 mg ORAL ANDA 27 sections
Sumatriptan Succinate HUMAN PRESCRIPTION DRUG LABEL 1 16714-040 INJECTION 6 mg SUBCUTANEOUS ANDA 27 sections
Sumatriptan Human Prescription Drug Label 1 16714-796 TABLET 25 mg ORAL ANDA 27 sections
Sumatriptan Human Prescription Drug Label 1 16714-797 TABLET 50 mg ORAL ANDA 27 sections
Sumatriptan Human Prescription Drug Label 1 16714-798 TABLET 100 mg ORAL ANDA 27 sections
Sumatriptan and Naproxen Sodium Human Prescription Drug Label 2 16714-891 TABLET, FILM COATED 85 mg ORAL ANDA 32 sections
IMITREX HUMAN PRESCRIPTION DRUG LABEL 1 21695-154 TABLET, FILM COATED 50 mg ORAL NDA 26 sections
Sumatriptan Succinate HUMAN PRESCRIPTION DRUG LABEL 1 21695-872 TABLET 25 mg ORAL ANDA 27 sections
Sumatriptan Succinate HUMAN PRESCRIPTION DRUG LABEL 1 21695-873 TABLET 50 mg ORAL ANDA 27 sections
Sumatriptan Succinate HUMAN PRESCRIPTION DRUG LABEL 1 21695-874 TABLET 100 mg ORAL ANDA 27 sections